Results 81 to 90 of about 3,155 (113)

[Determinants of access to dental health in Spain]. [PDF]

Aten Primaria
Ruiz-Campo S, Zuniga-Jara S, Soria-Barreto K.   +2 more
europepmc   +1 more source

30-Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis. [PDF]

Hemasphere
Ocio EM, Perrot A, Moreau P, Mateos MV, Bringhen S, Martínez-López J, Martínez-López J, Karlin L, Wang SY, Oprea C, Li Y, Kodas E, San-Miguel J.   +12 more
europepmc   +1 more source

Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial. [PDF]

Haematologica
Puig N, Agulló C, Contreras T, Pérez JJ, Aires I, Calasanz MJ, García-Sanz R, Castro S, Martínez-López J, Martínez-López J, Rodríguez-Otero P, González-Calle V, González MS, Oriol A, Gutiérrez NC, Ríos-Tamayo R, Rosiñol L, Álvarez MÁ, Bargay J, González-Rodríguez AP, Alegre A, Escalante F, Iñigo MB, De la Rubia J, Teruel AI, De Arriba F, Palomera L, Hernández MT, López-Jiménez J, Reinoso M, García-Mateo A, Ocio EM, Bladé J, Lahuerta JJ, Cedena MT, Paiva B, Miguel JFS, Mateos MV.   +37 more
europepmc   +1 more source

[Same year, different source: variability in prevalence estimates of exposure to secondhand smoke in Spain]. [PDF]

Aten Primaria
Rey-Brandariz J, Blanco-Ferreiro A, Santiago-Pérez MI, Schiaffino A, Guerra-Tort C, Pérez-Ríos M.   +5 more
europepmc   +1 more source

[Lessons learned from the evaluation of the Third Addiction Prevention Plan of Navarre]. [PDF]

An Sist Sanit Navar
Baigorria Feltrin FN, Jauregui Elso M, Razkin Orobengoa JM, Puchol Martínez I.   +3 more
europepmc   +1 more source

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma. [PDF]

N Engl J Med
Costa LJ, Bahlis NJ, Perrot A, Nooka AK, Lu J, Pawlyn C, Mina R, Caeiro G, Kentos A, Hungria V, Reece D, Niu T, Mylin AK, Hansen CT, Teipel R, Besemer B, Dimopoulos MA, Zamagni E, Yoshihara S, Kim K, Min CK, Geerts P, Van Leeuwen-Segarceanu E, Tyczynska A, Reguera JL, Johansson M, Hansson M, Turgut M, Grey M, Sidana S, Rodriguez-Otero P, Martinez-Lopez J, Hashmi H, Carson R, Kobos R, Sun W, Lantz K, Seifert A, Briseno-Toomey D, O'Rourke L, Rubin M, Vieyra D, Kang L, Mateos MV, MajesTEC-3 Trial Investigators.   +44 more
europepmc   +1 more source

LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis). [PDF]

Leukemia
Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, Dytfeld D, Angelucci E, Vincent L, Perrot A, Benjamin R, van de Donk NWCJ, Ocio EM, Roccia T, Schecter JM, Koskinen S, Haddad I, Strulev V, Mitchell L, Buyze J, Filho OC, Einsele H, Moreau P.   +22 more
europepmc   +1 more source

[Effects of a personalised, adapted computerised cognitive stimulation programme versus stimulating leisure activities in younger and older adults with mild or subjective cognitive impairment. Protocol for a randomised controlled trial]. [PDF]

An Sist Sanit Navar
Gómez-Soria I, Oliván-Blázquez B, Aguilar-Latorre A, Cuenca-Zaldívar JN, Magallón-Botaya RM, Calatayud E.   +5 more
europepmc   +1 more source

Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance. [PDF]

J Clin Oncol
Mateos MV, Martínez-López J, Martínez-López J, Rodriguez Otero P, González-Calle V, Gonzalez MS, Oriol A, Gutiérrez NC, Ríos-Tamayo R, Rosiñol L, Alvarez Rivas MA, Bargay J, Gonzalez-Rodriguez AP, Alegre A, Escalante F, Iñigo Rodríguez MB, De La Rubia J, Teruel AI, de Arriba F, Palomera L, Hernández MT, Lopez Jiménez J, Reinoso-Segura M, García Mateo A, Ocio EM, Paiva B, Puig N, Cedena MT, Bladé J, Lahuerta JJ, San-Miguel JF, Spanish Myeloma Group (GEM-Pethema).   +31 more
europepmc   +1 more source